Impact of Bacille Calmette-Guérin revaccination on serum IgE levels in a randomized controlled trial

AUTOR(ES)

Peleteiro, Thaís Silva, Oliveira, Evelin Santos, Conceição, Elisabete Lopes, Nascimento-Sampaio, Francisco, Alcântara-Neves, Neuza Maria, Mendes, Carlos Mauricio Cardeal, Bessa, Theolis Costa Barbosa

FONTE

Rev. Soc. Bras. Med. Trop.

DATA DE PUBLICAÇÃO

2018-02

RESUMO

Abstract INTRODUCTION: Bacille Calmette-Guérin (BCG) downmodulates allergen-specific IgE levels and prevents other atopic responses in experimental models but fails to protect against respiratory allergies. Human responsiveness to BCG is variable and may interfere with protection. METHODS: Multivariate models were evaluated to test the possible effect of responsiveness (assessed by IFN-γ production) to BCG revaccination on the modulation of total and allergen-specific serum IgE levels in healthy volunteers participating in a randomized controlled trial. RESULTS: Serum total or Derp-specific IgE levels did not change regardless of the increase in IFN-γ levels. CONCLUSIONS: BCG responsiveness does not affect protection against atopy.

Documentos Relacionados

• Disseminated Bacille Calmette-Guérin disease in immunocompetent adult patients
• Mycobacterium bovis bacille Calmette–Guérin strains secreting listeriolysin of Listeria monocytogenes
• High-viability lyophilized Bacille Calmette-Guérin vaccine produced by deep-culture technique.
• Diminished efficacy of bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer
• Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection.